Lymphoma immunotherapy: Vaccines, adoptive cell transfer and immunotransplant

Immunotherapy

Volumn 1, Issue 5, 2009, Pages 809-824

  Brody, Joshua ^a   Levy, Ronald ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adoptive transfer; Chimeric antigen receptor; Clinical trial; Dendritic cell; Idiotype immunotherapy; Immunotransplant; Lymphoma; Vaccine

Indexed keywords

BISPECIFIC MONOCLONAL ANTIBODY CD3 CD19; CANCER VACCINE; CD3DELTA ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CHRONIC LYMPHOCYTIC LEUKEMIA CELL VACCINE; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; CYTOKINE; DENDRITIC CELL VACCINE; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 96; IMMUNOGLOBULIN IDIOTYPE KEYHOLE LIMPET HEMOCYANIN GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LYMPHOCYTE ANTIGEN RECEPTOR; MAST LIKE CELL VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD45; PREDNISOLONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CYTOKINE INDUCED KILLER CELL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; GLIOBLASTOMA; HUMAN; LYMPHOKINE ACTIVATED KILLER CELL; LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; GENE TRANSFER TECHNIQUES; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY; LYMPHOMA, NON-HODGKIN; RADIOTHERAPY; T-LYMPHOCYTES;

EID: 77953408913     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/IMT.09.50     Document Type: Review

References (109)

1. The Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89(11), 3909-3918 (1997).
2. Levy RR, Ganjoo MK, Leonard J, Vose J, Denney D: Results of a Phase III trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared with non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymphoma (fNHL). AACR Meeting Abstracts (2008).
3. Huff CA, Matsui W, Smith BD, Jones RJ: The paradox of response and survival in cancer therapeutics. Blood 107(2), 431-434 (2006). (Pubitemid 43076361)
4. Yang L, Carbone DP: Tumor-host immune interactions and dendritic cell dysfunction. Adv. Cancer Res. 92, 13-27 (2004). (Pubitemid 39458111)
5. Gabrilovich DI, Chen HL, Girgis KR et al.: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2(10), 1096-1103 (1996).
6. + T cells. J. Immunol. 149(3), 949-956 (1992).
7. Qin Z, Noffz G, Mohaupt M, Blankenstein T: Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J. Immunol. 159(2), 770-776 (1997). (Pubitemid 127484228)
8. Marx J: Cancer immunology. Cancer's bulwark against immune attack: MDS cells. Science 319(5860), 154-156 (2008).
9. Filipazzi P, Valenti R, Huber V et al.: Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25(18), 2546-2553 (2007). (Pubitemid 47041228)
10. Munn DH, Sharma MD, Hou D et al.: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114(2), 280-290 (2004). (Pubitemid 39071633)
11. Schnurr M, Chen Q, Shin A et al.: Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 105(6), 2465-2472 (2005). (Pubitemid 40387047)
12. Morse MA, Hobeika AC, Osada T et al.: Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112(3), 610-618 (2008).
13. Kaminski MS, Kitamura K, Maloney DG, Levy R: Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J. Immunol. 138(4), 1289-1296 (1987). (Pubitemid 17017921)
14. Timmerman JM, Czerwinski DK, Davis TA et al.: Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99(5), 1517-1526 (2002).
15. Shankaran V, Ikeda H, Bruce AT et al.: IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410(6832), 1107-1111 (2001). (Pubitemid 32391043)
16. Smyth MJ, Thia KY, Street SE et al.: Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 192(5), 755-760 (2000).
17. Malyguine A, Strobl S, Zaritskaya L, Baseler M, Shafer-Weaver K: New approaches for monitoring CTL activity in clinical trials. Adv. Exp. Med. Biol. 601, 273-284 (2007).
18. Nagorsen D, Servis C, Levy N et al.: Proteasomal cleavage does not determine immunogenicity of gp100-derived peptides gp100 209-217 and gp100 209-217T210M. Cancer Immunol. Immunother. 53(9), 817-824 (2004). (Pubitemid 39149909)
19. Maecker HT, Hassler J, Payne JK et al.: Precision and linearity targets for validation of an IFNγ ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol. 9, 9 (2008).
20. Janetzki S, Panageas KS, Ben-Porat L et al.: Results and harmonization guidelines from two large-scale international ELISPOT proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol. Immunother. 57(3), 303-315 (2008). (Pubitemid 350295382)
21. + T cells responding to antigen without requiring knowledge of epitope specificities. Blood 110(1), 201-210 (2007). (Pubitemid 47026836)
22. Suni MA, Maino VC, Maecker HT: Ex vivo analysis of T-cell function. Curr. Opin. Immunol. 17(4), 434-440 (2005).
23. Chahroudi A, Silvestri G, Feinberg MB: Measuring T cell-mediated cytotoxicity using fluorogenic caspase substrates. Methods 31(2), 120-126 (2003). (Pubitemid 37075896)
24. Miller RA, Maloney DG, Warnke R, Levy R: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N. Engl. J. Med. 306(9), 517-522 (1982). (Pubitemid 12175745)
25. Meeker TC, Lowder J, Maloney DG et al.: A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 65(6), 1349-1363 (1985). (Pubitemid 15057941)
26. Brown SL, Miller RA, Levy R: Antiidiotype antibody therapy of B-cell lymphoma. Semin. Oncol. 16(3), 199-210 (1989).
27. Houot R, Levy R: Idiotype vaccination for lymphoma: moving towards optimisation. Leuk. Lymphoma 50(1), 1-2 (2009).
28. Hurvitz SA, Timmerman JM: Current status of therapeutic vaccines for non-Hodgkin's lymphoma. Curr. Opin. Oncol. 17(5), 432-440 (2005).
29. Redfern CH, Guthrie TH, Bessudo A et al.: Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin. Oncol. 24(19), 3107-3112 (2006). (Pubitemid 46638948)
30. Inoges S, Rodriguez-Calvillo M, Zabalegui N et al.: Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst. 98(18), 1292-1301 (2006). (Pubitemid 44530725)
31. Barrios Y, Cabrera R, Yanez R et al.: Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma. Haematologica 87(4), 400-407 (2002). (Pubitemid 34297547)
32. Bendandi M, Gocke CD, Kobrin CB et al.: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 5(10), 1171-1177 (1999). (Pubitemid 29474422)
33. Hsu FJ, Caspar CB, Czerwinski D et al.: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood 89(9), 3129-3135 (1997). (Pubitemid 27229795)
34. Kwak LW, Campbell MJ, Czerwinski DK: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327(17), 1209-1215 (1992).
35. Inoges S, Lopez-Diaz de Cerio A, Zabalegui N et al.: Prolonged idiotypic vaccination against follicular lymphoma. Leuk. Lymphoma 50(1), 47-53 (2009).
36. Timmerman J: A Phase II trial to evaluate the efficacy of recombinant idiotype vaccines in untreated follicular non-Hodgkin|s lymphoma in the 'watch-and-wait' period. Presented at: ASCO Annual Meeting 2002 (Abstract 13).
37. Betting DJ, Kafi K, Abdollahi-Fard A, Hurvitz SA, Timmerman JM: Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas. J. Immunol. 181(6), 4131-4140 (2008).
38. Neelapu SS, Baskar S, Gause BL et al.: Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin. Cancer Res. 10(24), 8309-8317 (2004). (Pubitemid 40053391)
39. O'Mahony D, Morris JC, Quinn C et al.: A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin. Cancer Res. 13(3), 958-964 (2007). (Pubitemid 46340373)
40. Neelapu SS, Kwak LW, Kobrin CB et al.: Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat. Med. 11(9), 986-991 (2005).
41. Davis TA, Hsu FJ, Caspar CB et al.: Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma. Biol. Blood Marrow Transplant 7(9), 517-522 (2001).
42. McCormick AA, Kumagai MH, Hanley K et al.: Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proc. Natl Acad. Sci. USA 96(2), 703-708 (1999). (Pubitemid 29061272)
43. McCormick AA, Reddy S, Reinl SJ et al.: Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a Phase I clinical study. Proc. Natl Acad. Sci. USA 105(29), 10131-10136 (2008).
44. Kanter G, Yang J, Voloshin A, Levy S, Swartz JR, Levy R: Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines. Blood 109(8), 3393-3399 (2007). (Pubitemid 46572528)
45. Timmerman JM, Singh G, Hermanson G et al.: Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res. 62(20), 5845-5852 (2002). (Pubitemid 35204744)
46. Nicchitta CV: Re-evaluating the role of heat-shock protein-peptide interactions in tumour immunity. Nat. Rev. Immunol. 3(5), 427-432 (2003).
47. Wood C, Srivastava P, Bukowski R et al.: An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised Phase III trial. Lancet 372(9633), 145-154 (2008).
48. Testori A, Richards J, Whitman E et al.: Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-121 Study Group. J. Clin. Oncol. 26(6), 955-962 (2008).
49. Oki Y, McLaughlin P, Fayad LE et al.: Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer 109(1), 77-83 (2007). (Pubitemid 46120196)
50. + regulatory T cells toward an antileukemia response. Leukemia 22(5), 1007-1017 (2008). (Pubitemid 351689883)
51. MaierT, Tun-Kyi A, Tassis A et al.: Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 102(7), 2338-2344 (2003). (Pubitemid 37193567)
52. Di Nicola M, Zappasodi R, Carlostella C et al.: Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunological responses in indolent B cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood 2008.
53. Dessureault S, Noyes D, Lee D et al.: A Phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Ann. Surg. Oncol. 14(2), 869-884 (2007). (Pubitemid 46175338)
54. Dessureault S, Noyes D, Tao J et al.: Bystander-based immunotherapy for patients with mantle cell lymphoma (MCL): proof of principle. Blood 110, 4483 (2007).
55. Biagi E, Rousseau R, Yvon E et al.: Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin. Cancer Res. 11(19 Pt 1), 6916-6923 (2005). (Pubitemid 41428749)
56. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ: CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96(9), 2917-2924 (2000).
57. Wierda W: Membrane-Stable, Humanized CD154 gene therapy for patients with CLL. Blood 108, 2104 (2006).
58. Spaner DE, Hammond C, Mena J, Foden C, Deabreu A: A Phase I/II trial of oxidized autologous tumor vaccines during the 'watch and wait' phase of chronic lymphocytic leukemia. Cancer Immunol. Immunother. 54(7), 635-646 (2005).
59. Li J, Song W, Czerwinski DK et al.: Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J. Immunol. 179(4), 2493-2500 (2007).
60. Brody JA, Czerwinski WZ, Advani D et al.: Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Preliminary results of a Phase II trial of intra-tumoral CpG 7909. J. Clin. Oncol. 26, (Suppl). (2008) (Abstract 3003).
61. + T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J. Immunol. 178(11), 6840-6848 (2007).
62. Wrzesinski C, Restifo NP: Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Curr. Opin. Immunol. 17(2), 195-201 (2005). (Pubitemid 40343108)
63. Dudley ME, Wunderlich JR, Robbins PF et al.: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594), 850-854 (2002).
64. Dudley ME, Wunderlich JR, Yang JC et al.: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23(10), 2346-2357 (2005).
65. Dudley ME, Yang JC, Sherry R et al.: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin. Oncol. 2008.
66. Abrams SI, Brahmi Z: Target cell directed NK inactivation. Concomitant loss of NK and antibody-dependent cellular cytotoxicity activities. J. Immunol. 140(6), 2090-2095 (1988).
67. Mackinnon S, Papadopoulos EB, Carabasi MH et al.: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86(4), 1261-1268 (1995).
68. Porter DL, Antin JH: Adoptive immunotherapy for relapsed leukemia following allogeneic bone marrow transplantation. Leuk. Lymphoma 17(3-4), 191-197 (1995).
69. Khouri IF, Lee MS, Romaguera J et al.: Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann. Oncol. 10(11), 1293-1299 (1999).
70. Peggs KS, Hunter A, Chopra K et al.: Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 365(9475), 1934-1941 (2005).
71. Albertini MR, Sosman JA, Hank JA et al.: The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2. Cancer 66(12), 2457-2464 (1990).
72. Berdeja JG, Hess A, Lucas DM et al.: Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin. Cancer Res. 13(8), 2392-2399 (2007). (Pubitemid 46698589)
73. Benyunes MC, Higuchi C, York A et al.: Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplant 16(2), 283-288 (1995).
74. Lister J, Rybka WB, Donnenberg AD et al.: Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period. Clin. Cancer Res. 1(6), 607-614 (1995).
75. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS: A Phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol. Blood Marrow Transplant 11(3), 181-187 (2005).
76. +-selected hematopoietic cell transplantation. Blood 102(6), 2004-2013 (2003).
77. Schuster S, Levine B, Nasta S et al.: Adoptive immunotherapy with autologous CD25-depleted and CD3/CD28-costimulated T-cells (ACTC) enhances numeric and functional lymphocyte recovery after cyclophosphamide-fludarabine chemotherapy in patients with low-grade follicular lymphoma. Blood 110, 126 (2007).
78. Bollard CM, Aguilar L, Straathof KC et al.: Cytotoxic T lymphocyte therapy for Epstein-Barr virus + Hodgkin's disease. J. Exp. Med. 200(12), 1623-1633 (2004). (Pubitemid 40094186)
79. Bollard CM, Gottschalk S, Leen AM et al.: Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110(8), 2838-2845 (2007). (Pubitemid 350006936)
80. Clark RA, Chong BF, Mirchandani N et al.: A novel method for the isolation of skin resident T cells from normal and diseased human skin. J. Invest. Dermatol. 126(5), 1059-1070 (2006).
81. Walker RE, Bechtel CM, Natarajan V et al.: Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 96(2), 467-474 (2000). (Pubitemid 30463364)
82. + cytotoxic T lymphocytes. Mol. Ther. 9(4), 577-586 (2004). (Pubitemid 38578808)
83. Chen E, Press O, Jensen M: CD8 immunomagnetic selection and interleukin-15 (IL-15) facilitate the isolation of human CD8 cytotoxic T-lymphocytes (CTL) genetically engineered to express an anti-CD20 chimeric T-cell receptor (cTCR). J. Clin. Oncol. 22(Suppl. 14), 2542 2004 (2004).
84. ParkJR, Digiusto DL, Slovak M et al.: Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther. 15(4), 825-833 (2007). (Pubitemid 46432004)
85. Till BG, Jensen MC, Wang J et al.: Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112(6), 2261-2271 (2008).
86. Brentjens R, Hollyman D, Weiss M et al.: A Phase I trial for the treatment of purine analog-refractory chronic lymphocytic leukemia using autologous T cells genetically targeted to the B cell specific antigen CD19. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 3045).
87. Cooper LJ, Ausubel L, Gutierrez M et al.: Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma. Cytotherapy 8(2), 105-117 (2006). (Pubitemid 43675197)
88. Lamers CH, van Elzakker P, Langeveld SC, Sleijfer S, Gratama JW: Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene. Cytotherapy 8(6), 542-553 (2006). (Pubitemid 44869854)
89. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC: Specific recognition and killing of glioblastoma multiforme by interleukin13-zetakine redirected cytolytic T cells. Cancer Res. 64(24), 9160-9166 (2004). (Pubitemid 39665531)
90. Bargou R, Leo E, Zugmaier G et al.: Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321(5891), 974-977 (2008).
91. Brentjens RJ, Santos E, Nikhamin Y et al.: Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin. Cancer Res. 13(18 Pt 1), 5426-5435 (2007). (Pubitemid 47510370)
92. Friedmann-Morvinski D, Bendavid A, Waks T, Schindler D, Eshhar Z: Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood 105(8), 3087-3093 (2005). (Pubitemid 40504325)
93. Jensen M, Popplewell L, DiGiusto D et al.: A first-in-human clinical trial of adoptive therapy using CD19-specific chimeric antigen receptor re-directed T cells for recurrent/refractory follicular lymphoma. Blood 110, 288 (2007).
94. Imai C, Mihara K, Andreansky M et al.: Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18(4), 676-684 (2004). (Pubitemid 38500185)
95. + cytotoxic lymphocytes for adoptive immunotherapy. J. Immunol. 179(7), 4910-4918 (2007).
96. Pule MA, Savoldo B, Myers GD et al.: Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14(11), 1264-1270 (2008).
97. + T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 118(1), 294-305 (2008).
98. Riddell SR, Elliott M, Lewinsohn DA et al.: T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat. Med. 2(2), 216-223 (1996). (Pubitemid 26057556)
99. Berger C, Flowers ME, Warren EH, Riddell SR: Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107(6), 2294-2302 (2006). (Pubitemid 43345547)
100. Hata A, Asanuma H, Rinki M et al.: Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N. Engl. J. Med. 347(1), 26-34 (2002). (Pubitemid 34728954)
101. Antin JH, Guinan EC, Avigan D et al.: Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant 11(3), 213-222 (2005). (Pubitemid 40287920)
102. Rapoport AP, Stadtmauer EA, Aqui N et al.: Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med. 11(11), 1230-1237 (2005). (Pubitemid 43093671)
103. Borrello I, Sotomayor EM, Rattis FM, Cooke SK, Gu L, Levitsky HI: Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 95(10), 3011-3019 (2000). (Pubitemid 30321148)
104. Kochenderfer JN, Simpson JL, Chien CD, Gress RE: Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT. Blood 110(1), 450-460 (2007).
105. + T cells. J. Exp. Med. 202(7), 907-912 (2005). (Pubitemid 41396891)
106. Brody JD, Goldstein MJ, Czerwinski DK, Levy R: Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Blood 113(1), 85-94 (2009).
107. Cho HI, Hong YS, Lee MA et al.: Adoptive transfer of Epstein-Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas. Int. J. Hematol. 83(1), 66-73 (2006).
108. Surveillance, epidemiology and end results. http://seer.cancer.gov/ statfacts/html/nhl.html
109. Surveillance, epidemiology and end results - cancer statistics fact sheets. http://seer.cancer.gov/statfacts